EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

By sjmartinez • October 30, 2022

Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, Srivatsan ES. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer. 2022 Oct 26:188827. doi: 10.1016/j.bbcan.2022.188827. Epub ahead of print. PMID: 36309124.

Tags: Epidermal growth factor receptor, Head and neck cancer, Head and neck squamous cell carcinoma, Hematology/Oncology, immunotherapy, Monoclonal antibodies, Publications, Receptor tyrosine kinase, Small molecular inhibitors, Veterans Administration

Related Posts

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson[...]

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J. A[...]